Dyno Therapeutics

• AI-driven sequence design of adeno-associated virus (AAV) capsids for gene delivery
• High-throughput in vivo data generation to train machine learning models and validate vector performance
• Engineered vector specificity for tissues including central nervous system (CNS), eye, muscle, and liver
• Optimization of packaging efficiency, transduction rate and off-target de-targeting to enhance safety
• Platform approach enabling rapid iteration of capsid libraries and machine-guided design cycles
• Scalable in silico + in vivo workflow to reduce time and cost versus traditional vector development
• Partnership-centric licensing and collaboration model with top biopharma companies
• Proprietary machine-learning frameworks (e.g., low-shot, efficient design regimes) to accelerate candidate discovery
• Access to improved gene-therapy delivery solutions enabling broader disease and patient coverage
• Integration of biological, computational and engineering expertise to commercialize next-gen genetic medicines

Dyno Therapeutics is a biotechnology platform company that combines artificial intelligence, high-throughput biology and gene-therapy engineering to deliver next-generation genetic medicines. The company’s mission is to enable safe, effective and accessible gene delivery by designing high-performance AAV capsids optimized for tissues such as the central nervous system, eye and muscle. By harnessing deep learning and large in vivo data sets, Dyno creates novel viral vector designs that outperform traditional vectors in packaging, transduction, specificity and safety.

The platform approach integrates machine-learning guided sequence generation, empirical data from animal studies and advanced engineering workflows to iterate capsid libraries much faster than conventional methods. This accelerated design cycle allows Dyno to partner with leading biopharma companies and license its vectors for use in gene-therapy programs across many therapeutic areas. The result is reduced development timelines, lower costs and greater probability of clinical success.

Dyno’s AI-driven strategy includes low-shot, efficient design regimes that require far fewer experimental iterations to achieve breakthrough performance. The company emphasizes tissue targeting, off-target de-targeting, immune-evasion and manufacturability as core optimization goals. With its platform, Dyno is well-positioned to expand the range of treatable diseases by improving vector delivery into previously hard-to-reach organs and cell types.

For biotechnology and pharmaceutical companies developing gene therapies, Dyno offers a transformative vector-engineering capability to accelerate therapeutic development and expand patient access. By leveraging data-driven insights, machine-guided design and rigorous experimental validation, Dyno is setting a new standard for the engineering of gene-delivery vehicles. For any organization seeking to partner at the frontier of gene-therapy innovation, Dyno Therapeutics represents a strategic partner with deep biological, computational and translational expertise.